Combination therapies against cancer targeting CD38 and TGF-β
The present disclosure relates to combination cancer therapies targeting CD38 and TGF-β using antibodies specific for these targets. Also provided are compositions useful in the therapies.
1 . A method of treating a CD38-positive cancer in a human patient in need thereof, comprising administering to the patient
an anti-CD38 antibody that has heavy chain CDR1 (HCDR1), HCDR2, HCDR3, light chain CDR1 (LCDR1), LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 15-20, respectively, and
an anti-TGF-β antibody or an antigen-binding fragment thereof that has HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 5-10, respectively,
wherein the cancer is multiple myeloma that is refractory to treatment with Ab2, and the administering of the anti-CD38 antibody and the anti-TGF-β antibody or antigen-binding fragment slows cancer growth.
2 . The method of claim 1 , wherein the anti-CD38 antibody comprises a heavy chain variable domain (V H ) and a light chain variable domain (V L ) comprising the amino acid sequences of SEQ ID NOs: 13 and 14, respectively; and wherein the anti-TGF-β antibody comprises a V H and a V L comprising the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.
3 . The method of claim 2 , wherein the anti-CD38 antibody has a heavy chain (HC) and a light chain (LC) comprising the amino acid sequences of SEQ ID NOs: 11 and 12, respectively; and wherein the anti-TGF-β antibody has an HC and an LC comprising the amino acid sequences of SEQ ID NOs: 1 and 2, respectively.
4 . A method of treating a CD38-positive cancer in a human patient in need thereof, comprising administering to the patient an anti-CD38 antibody and an anti-TGF-β antibody or an antigen-binding fragment thereof, wherein the anti-CD38 antibody:
a) has HCDR1-3 and LCDR1-3 comprising the amino acid sequences of SEQ ID NOs: 15-20, respectively;
b) has a heavy chain variable domain (V H ) and a light chain variable domain (V L ) comprising the amino acid sequences of SEQ ID NOs: 13 and 14, respectively; or
c) has a heavy chain (HC) and a light chain (LC) comprising the amino acid sequences of SEQ ID NOs: 11 and 12, respectively; and
wherein the anti-TGF-β antibody:
a) has HCDR1-3 and LCDR1-3 comprising the amino acid sequences of SEQ ID NOs: 5-10, respectively;
b) has a V H and a V L comprising the amino acid sequences of SEQ ID NOs: 3 and 4, respectively; or
c) has an HC and an LC comprising the amino acid sequences of SEQ ID NOs: 1 and 2, respectively,
wherein the cancer is multiple myeloma that is refractory to treatment with Ab2, and the administering of the anti-CD38 antibody and the anti-TGF-β antibody or antigen-binding fragment slows cancer growth.
5 . The method of claim 1 , wherein the anti-CD38 antibody comprises a human IgG 1 Fc region and the anti-TGF-β antibody comprises a human IgG 4 Fc region.
6 . A method of treating multiple myeloma in a human patient in need thereof, comprising administering to the patient an anti-CD38 antibody that comprises a heavy chain variable domain (V H ) amino acid sequence of SEQ ID NO: 13 and a light chain variable domain (V L ) amino acid sequence of SEQ ID NO: 14, and an anti-TGF-β antibody that comprises a V H amino acid sequence of SEQ ID NO: 3 and a V L amino acid sequence of SEQ ID NO: 4, wherein the cancer is multiple myeloma that is refractory to treatment with Ab2, and the administering of the anti-CD38 antibody and the anti-TGF-β antibody or antigen-binding fragment slows cancer growth.
7 . A method of treating multiple myeloma in a human patient in need thereof, comprising administering to the patient an anti-CD38 antibody that comprises a heavy chain (HC) amino acid sequence of SEQ ID NO: 11 and a light chain (LC) amino acid sequence of SEQ ID NO: 12, and an anti-TGF-β antibody that comprises an HC amino acid sequence of SEQ ID NO: 1 and an LC amino acid sequence of SEQ ID NO: 2, wherein the cancer is multiple myeloma that is refractory to treatment with Ab2, and the administering of the anti-CD38 antibody and the anti-TGF-β antibody or antigen-binding fragment slows cancer growth.
8 . The method of claim 1 , wherein the anti-CD38 antibody and the anti-TGF-β antibody or fragment are administered to the patient sequentially.
9 . The method of claim 1 , wherein the treatment results in less bone destruction than treatment with the anti-CD38 antibody alone.
10 . The method of claim 1 , wherein the treatment enhances bone healing.
11 . The method of claim 1 , wherein the treatment further comprises dexamethasone.